Significant Differences for Methods of Measuring Albumin

Share this content:
Significant Differences for Methods of Measuring Albumin
Significant Differences for Methods of Measuring Albumin

TUESDAY, Feb. 7, 2017 (HealthDay News) -- Significant differences are seen for immunochemical, bromcresol green (BCG), and bromcresol purple (BCP) methods of albumin measurement, according to a study published online Jan. 20 in Clinical Chemistry.

Lorin M. Bachmann, Ph.D., from the Virginia Commonwealth University in Richmond, and colleagues prepared pools from residual patient serum (50 samples) and heparin plasma (48 samples) from patients without renal disease, and 53 serum samples from patients with kidney failure before hemodialysis. The authors measured albumin in all samples, and in ERM-DA470k/IFCC reference material (RM) by three, nine, and 12 immunochemical, BCG, and BCP methods, respectively.

The researchers found that two immunochemical, five BCG, and 10 BCP methods recovered the RM value within its uncertainty. Compared with the RM value, one immunochemical and three BCG methods were biased. Based on recovery and results of error analyses the Tina-quant immunochemical method was chosen as the reference measurement procedure. For BCG versus Tina-quant, the mean biases were 1.5 to 13.9 percent, and these were larger at lower albumin concentrations. The mean biases of BCP methods were −5.4 to 1.2 percent, regardless of albumin concentration. For all method types, biases were generally higher for plasma than for serum samples. Biases were lower for serum from patients on hemodialysis versus patients without kidney disease for most measurement procedures.

"Significant differences among immunochemical, BCG, and BCP methods compromise interpretation of serum albumin results," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »